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Epstein–Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), also referred to as human herpesvirus 8
(HHV-8), are human gammaherpesviruses associated with numerous lymphomas and proliferative diseases in humans. We
were interested in the protein expression patterns of specific latent and lytic proteins from the EBV genome in two
body-cavity-based lymphoma cell lines, BC-1 and BC-2, which are coinfected with EBV and KSHV. BC-1 and BC-2 were
analyzed using specific antibodies to latent proteins known to be essential for EBV immortalization of human primary
B-lymphocytes in vitro and lytic antigens important for EBV replication and production of viral progeny. The coinfected cell
lines are compared with two singly infected KSHV cell lines to determine whether antibodies against EBV-specific proteins
cross-reacted against KSHV antigens. All the KSHV-infected cell lines express the KSHV-specific latency-associated nuclear
antigen (LANA) with a specific pattern in the nucleus. This staining was distinct from that seen for EBNA1 in the EBV
coinfected lines BC-1 and BC-2 staining the nucleus as a diffused pattern throughout the nucleus with denser staining in
some regions. The coinfected cell lines all express EBNA1 and LMP1 at lower levels compared with singly infected EBV
lymphoblastoid cell lines (LCLs). However, the essential latent antigens EBNA2, EBNA3A, and EBNA3C are not expressed in
BC-1 and BC-2. This indicates potential regulation of EBV latent gene expression by KSHV-encoded viral or KSHV-induced
cellular gene products. Additionally, lytic gene expression analysis demonstrated that BZLF1 and BMRF1 are expressed
along with other early antigens (EA-D). A specific protein is detected in a singly infected KSHV cell line with cross-reactivity
to antibodies that detected the EA-D complex. Moreover, in all the cell lines infected with EBV, KSHV, or EBV and KSHV,
human serum with antibodies against KSHV antigens recognizes specific viral antigens ;110 and 41–42 kDa, suggesting that
human antibodies against KSHV-specific antigens can cross-react with similar EBV antigens. Therefore these data suggest
that the EBV pattern of gene expression in the coinfected cell lines is a type II pattern of latency also seen in other human
tumors including nasopharyngeal carcinoma and Hodgkin’s lymphoma. This distinct pattern of latent and lytic gene
expression in these cell lines may provide clues as to the selection for coinfection in these body cavity based lymphomas
in immunocompromised hosts. © 1999 Academic Press
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sINTRODUCTION
EBV is a human gammaherpesvirus with tropism for
uman B-lymphocytes (Kieff et al., 1985). Another re-
ently discovered gammaherpesvirus, KSHV, with similar
enomic organization to herpesvirus saimiri belonging to
he subfamily Rhadinovirus has been found associated
ith AIDS-related and other classes of Kaposi’s sarco-
as (Chang et al., 1994; Neipel et al., 1997). KSHV was
dentified in primary effusion lymphomas (PELs) also
eferred to as body-cavity-based lymphomas (Cesarman
t al., 1995a; Ganem, 1997), and in multicentric Castle-
an’s disease (Gessain et al., 1996; Gessain, 1997; Tis-
ier et al., 1998). The virus also is seen in dendritic cells
f patients with multiple myeloma and is still under
nvestigation (Rettig et al., 1997). Body-cavity lymphomas
een in AIDS patients often carry EBV as well as this new
1 To whom reprint requests should be addressed. Fax: (734) 764-
t562; E-mail: esrobert@umich.edu.
042-6822/99 $30.00
opyright © 1999 by Academic Press
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18ammaherpesvirus, KSHV (Cesarman et al., 1995b). Cell
ines including BC-1 and BC-2 carrying both EBV and
SHV were established from body-cavity-based lympho-
as (Cesarman et al., 1995b). Another two cell lines,
C-3 and BCBL-1, singly infected with KSHV also were
stablished in vitro (Arvanitakis et al., 1996; Renne et al.,
996).
EBV typically establishes three distinct programs of
atency based on the specific latent genes expressed
uring latent infection (Rickinson and Kieff, 1996). A full
epertoire of latent gene expression includes ;11 tran-
cripts (see Kieff, 1996; Rickinson and Kieff, 1996 for
eview). These are the Epstein–Barr virus nuclear anti-
ens (EBNA) LP, 1, 2, 3A, 3B, and 3C; latent membrane
roteins (LMPs) 1, 2A, and 2B; the Epstein–Barr virus
arly RNAs (EBERs); and the BARF0 transcripts (Sample
t al., 1991; Tomkinson, 1992, 1993; Kaye, 1993; Izumi,
997). Type I latency is usually found in endemic and
poradic Burkitt’s lymphomas with the predominant la-ent antigen EBNA1 being expressed (Rickinson and
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19VIRAL ANTIGEN EXPRESSION IN COINFECTED BODY-CAVITY-BASED LYMPHOMAS CELLSieff, 1996). Type II latency typically associated with the
xpression of EBNA1 and the LMPs and type III associ-
ted with expression of all the latent proteins (Rickinson
nd Kieff, 1996). The EBERs and BARF0 transcripts are
sually detected in all types of latency (Kieff, 1996).
To date KSHV and EBV latent and lytic protein expres-
ion in infected body-cavity lymphomas has been mini-
ally characterized. The latency-associated nuclear an-
igen (LANA) has been detected in all KSHV-associated
esions (Kedes et al., 1997). These coinfected and singly
nfected cell lines represent a unique set of reagents for
nalysis of viral gene regulation that can potentially oc-
ur between two related gammaherpesviruses isolated
rom primary effusion lymphomas. Therefore we at-
empted to undertake a more through investigation into
he expression of the latent and lytic genes in these EBV
nd KSHV coinfected cell lines.
Other attempts to obtain more of the previously de-
cribed coinfected cell lines were unsuccessful, and
ttempts using in vitro cultures so far has not led to
oinfected lines. Additionally, in BC-1 cells it was dem-
nstrated that the KSHV DNA was induced to replicate
ith the chemical inducer n-butyrate (Miller et al., 1997).
revious analysis of coinfected cell lines indicated to be
oinfected with type I EBV (Horenstein et al., 1997) relied
ainly on reverse transcription pcr assays from two
roups looking at viral transcripts with conflicting results
Horenstein et al., 1997; Szekely et al., 1998). Therefore
e decided to investigate protein levels in two estab-
ished coinfected lines, specifically the essential latent
roteins for B-lymphocyte transformation in vitro and lytic
enes known to be crucial for production of viral prog-
ny. These studies also investigated the possibility that
ntibodies to some of the EBV proteins would cross-
eact with KSHV proteins due to similarities in a number
f viral-encoded lytic proteins. We found that the pattern
f latency is similar to that of type II seen in nasopha-
yngeal carcinoma and Hodgkin’s lymphomas (Rickinson
nd Kieff, 1996). These results were distinct from that
bserved by another group in BC-1 cells where no LMP1
ignal was detected (Szekely et al., 1998). EBNA1 was
bserved in both coinfected cell lines as well as LMP1 in
ur studies. These previous studies demonstrated that
he Qp promoter was used for EBNA1 expression similar
o that seen in EBV-infected Burkitt’s lymphoma cell lines
Rickinson and Kieff, 1996; Horenstein et al., 1997;
zekely et al., 1998). The level of EBNA1 and LMP1 seen
n the coinfected cell lines were relatively lower than that
een in cell lines singly infected with EBV. LANA was
bserved in all KSHV-infected cell lines investigated, and
ome cross-reactivity was observed between EBV and
SHV lytic antigens as determined by polyclonal antibod-
es. We suggest that the presence of the KSHV virus may
rovide regulatory elements in trans, resulting in the
own modulation of essential EBV genes, or induce
ellular factors that may regulate these promoters. This Tay be crucial for co-existence of these two viruses in
stablishment of body-cavity-based lymphomas. Alterna-
ively, cellular genes may directly play a role in regulating
he gene expression program of both EBV as well as
HV-8.
RESULTS
xpression of EBV latent proteins EBNA1 and LMP1
n coinfected BC-1 and BC-2 cells
Western blotting of membranes with fractionated cell
ysates from BC-1 and BC-2 using adsorbed, specific
BNA human serum (designated as HS-1 in this study)
apable of detecting EBNA1, EBNALP, EBNA2, EBNA3A,
B, and 3C (see Robertson et al., 1994) demonstrated
hat EBNA1 is expressed in both BC-1 and BC-2 (Fig. 1).
FIG. 1. Western blot analysis showing EBNA protein expression in
he PEL lines BC-1 and BC-2. Lanes 1 and 2 represent fractionated
roteins from cell lysate obtained from 1 million cells prepared from
C-1 and BC-2, respectively. Positive control cell lines are in lane 3
rom a recently derived LCL-infected with B95–8 virus LCL1; and lane
represent B95–8. BJAB is an EBV-negative cell line. Protein from
ontrol cell lines was prepared from cell lysate of 200,000 cells in each
ane. Western blot is using a human serum (HS-1) with reactivity to the
ntire panel of EBV latent EBNA proteins (Robertson et al., 1994).
rotein markers are indicated on the left and the specific positions of
he EBNA proteins are on the right. Protein fractionation was analyzed
sing an 8% SDS–PAGE gel system.he intensity of EBNA1 signal was also lower in BC-1
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20 CALLAHAN ET AL.han in BC-2. However, this EBNA1 band had a mobility
hat was comparable to that of the EBNA2 band in LCL1
nd B95–8, indicating that this was a distinct isolate of
BV to that from BC-1 and is possibly comigrating with
he EBNA2 protein. EBNALP was detected in the B95–8
ane as a band ;40 kDa in size. Typically EBNALP can
e seen as a ladder of bands in LCLs due to the multiple
plicing of the BamHI W repeats that spans the open
eading frame but sometimes can be more specific in
ize after cell lines are established in culture for long
eriods. A number of faint bands were noted in the
egion from 17 to 73 kDa, albeit less pronounced com-
ared with EBNA1 and EBNA2, indicating that there is a
ossibility that EBNALP was expressed. EBNA3A, 3B,
nd 3C were clearly seen in the LCL1 and B95–8 lanes.
owever, no signal was observed for EBNA3 protein
xpression in BC-1 and BC-2 even when the number of
ells in the cell lysates were increased fivefold in lanes
and 2 (compare lanes 1 and 2 with lanes 3 and 4, Fig.
). This result suggests that EBNA1 is predominantly
xpressed at detectable levels in BC-1 and BC-2.
To analyze the expression of the essential EBV LMP1
n these coinfected cells by Western blot, we used a
pecific hybridoma to the LMP1 S12 (Mann et al., 1985).
igure 2 demonstrated that LMP1 is expressed in these
ells at lower levels by visual observation of the bands in
anes 1 and 2 compared to lanes 3 and 4 from control cell
ines. Lanes 1 and 2 had five times the amount of cell
ysate as control lanes 3 and 4 and control lane 5 in Fig.
. A conservative estimate of the intensity of the bands
ased on these visual comparisons indicates that the
evels of LMP1 in the controls were about twofold greater
han in lanes 1 and 2 of Fig. 2. Therefore by a visual
nspection we estimate that the levels of LMP1 in BC-1
nd BC-2 were 10-fold lower than that seen in the posi-
ive control cell lines. A predominant lower band typical
f the D1LMP1 protein is seen in B95–8 control cells
FIG. 2. BC-1 and BC-2 express LMP1. Western blot analysis of
ractionated proteins from cell lysates from BC-1 and BC-2 body-cavity-
ased lymphoma lines using an LMP1-specific monoclonal antiserum
12 (Robertson et al., 1994). Cell lines were prepared as described in
ig. 1. Protein markers are indicated on the left and the position of
MP1 is indicated on the right. D1LMP1 also is indicated. Note that a
mall amount of D1LMP1 was seen in BC-1 and BC-2.lane 4, Fig.2). A band migrating at the same position in aC-1 and BC-2 (lanes 1 and 2) indicates that D1LMP1 is
xpressed in these cells (compare lanes 1 and 2 with
ane 4, Fig.2).
Immunofluorescence analysis of these essential pro-
eins in BC-1 and BC-2 was performed to support our
ata seen in Western blotting experiments that demon-
trated that EBNA1 and LMP1 was expressed in BC-1
nd BC-2 cells. Figure 3, left, is stained with an anti-
MP1 hybridoma antibody S12 (Mann et al., 1985). The
iddle panel is stained with a human serum that specif-
cally recognizes only EBNA1 and was previously ad-
orbed with B cell antigens from an EBV-negative BJAB;
nd the right panel is stained with a human serum that
ecognizes the LANA antigen from KSHV also adsorbed
gainst EBV and B cell antigens. An EBV-positive cell
ine, IB4, was used as control in second row from the top.
n this cell line, LMP1 had intense staining of the B cell
embrane with .90% of the cells positive for LMP1
taining. The typical LMP1 staining pattern was ob-
erved showing the aggregation of LMP1 at the cell
embrane. All of the IB4 cells stained positive for EBNA1
s indicated by the intense punctate staining of the
ucleus shown in the middle panel, second row from the
op. No specific staining was observed in the IB4 LANA
taining (right panel). The bottom two rows of Fig. 3
hows the specific staining for LMP1 and EBNA1 in the
oinfected BC-1 and BC-2 cell lines. We observed low-
evel staining of LMP1 at the cell membrane with minimal
ggregation compared with that seen in IB4 with the
ypical patching at the membrane (see left panel, bottom
ows of Fig. 3). EBNA1 staining was also low with some
unctate staining of the nucleus compared to that seen
n the IB4 cells (middle bottom rows, Fig.3). This data
uggests that the EBV latent antigens are expressed at
ower levels in these coinfected cells compared with a
ingly infected EBV cell line. LANA staining of these
oinfected cells, however, demonstrated that the nucleus
as stained in .90% of the cells within distinct loci
shown in the right lower panel, bottom rows of Fig. 3).
ome weak nonspecific cytoplasmic staining is seen in
he EBV-negative BJAB cells from the secondary goat
nti-human FITC and is not seen when using the specific
MP1 hybridoma (compare top left panel with middle
nd right panel in BJAB). These data together with the
estern blots suggest that BC-1 and BC-2 express the
ajor EBV latent proteins EBNA1 and LMP1 albeit at
ower levels than that seen in the singly infected EBV-
nfected cells.
ANA and EBNA1 were specifically detected in BC-1
nd BC-2 using human polyclonal serum
The previous analysis using human polyclonal serum
hat detected all the EBV EBNA latent proteins indicated
hat EBNA1 in BC-1 and BC-2 were potentially migrating
t varying sizes and that one of the size may be comi-
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21VIRAL ANTIGEN EXPRESSION IN COINFECTED BODY-CAVITY-BASED LYMPHOMAS CELLSFIG. 3. Immunofluorescence analysis demonstrates expression of EBNA1, LMP1, and LANA in BC-1 and BC-2. Cells were fixed in methanol:acetone
1:1) and incubated antibody against LMP1 (S12 monoclonal), EBNA1 (human serum adsorbed against B cell antigens, HS-2) and LANA (human serum
rom a Kaposi’s-sarcoma-positive patient adsorbed against B cell and EBV latent antigens, HS-3). S12 monoclonal hybridoma supernatant was used
ndiluted, antiEBNA1 serum was used at 1:50 dilution, and anti LANA serum diluted at 1:1000 in phosphate-buffered saline with 1 mM sodium azide.
econdary antibodies for detection of the monoclonal against LMP1 was goat anti-mouse FITC and for detection of the human polyclonal antibody
gainst EBNA1 and LANA was goat anti-human FITC at dilutions of 1:1000, respectively. Ninety-four percent of the BC-1 and 91% of the BC-2 cells
ere positive for EBNA1 compared with 100% for IB4. BC-1 and BC-2 appears to have nontypical cytoplasmic LMP1 staining in ,30% of the cell
opulation. LANA was detected in 100% of BC-1 and BC-2 cells. IB4 is an EBV-positive control cell line, BJAB is not infected with EBV and was used
s a negative control. BC-1 and BC-2 are coinfected with EBV and KSHV. Images were analyzed using a PCM 2000 Nikon confocal microscope.
g
l
s
c
l
l
s
E
(
a
t
L
H
L
d
o
d
a
a
K
t
d
i
t
r
T
E
l
p
f
t
W
p
t
n
(
a
p
E
w
l
s
t
u
a
E
s
o
c
o
K
t
a
g
b
n
s
u
E
L
B
i
5
c
b
s
f
c
u
22 CALLAHAN ET AL.rating with the size seen for EBNA2 (Fig. 1, compare
anes 2 with 4 and 5). Therefore we screened a human
erum absorbed against B cell antigens that was spe-
ific for EBNA1 detection and designated as HS-2. Cell
ysates from BC-1 and BC-2 were fractionated and ana-
yzed by Western blot for detection of EBNA1. The results
howed that EBNA1 from BC-1 migrated faster than
BNA1 from BC-2 indicating a different isolate of EBV
Fig. 4B, lanes 1 and 2). Similarly we blotted for LANA
ntigen using a specific human serum that recognizes
he LANA antigen and designated as HS-3. We detected
ANA expression in each cell line infected with KSHV.
owever, there was a migration difference observed for
ANA in BC-1 and BC-2 (Fig. 4A, lanes 1 and 2). These
ifferences in migration have been consistent in numer-
us other blots (data not shown). Interestingly, the size
ifference in LANA on SDS–PAGE for a protein of .1000
mino acids may have implications for potential amino
cid differences in the LANA protein sequence in the two
SHV-infected cell lines or varying levels of posttransla-
ional modification. This suggests that there is a potential
ifference in LANA protein sequence similar to that seen
n the EBNA3 genes from EBV types I and II. Alternatively,
he elements within orf73 may have varying number of
epeats similar to the EBNA1 gene (Kieff, 1996).
he essential EBV latent antigens EBNA2 and
BNA3C are not expressed in BC-1 and BC-2
In an effort to determine whether other major EBNA
atent antigens crucial for EBV immortalization of human
rimary B-lymphocytes are expressed in these coin-
ected lines, we obtained specific monoclonal antibodies
FIG. 4. EBNA1 and LANA are detected in BC-1 and BC-2 by Western
lotting analysis. EBNA1 migrates at different positions on SDS–PAGE
imilar to LANA. Lanes 1 and 2 (A and B) contain cell lysates prepared
rom 1 million cells. LCL1 and B95–8 were used as EBV-positive
ontrols and BJAB as a negative control. The human polyclonal serum
sed is as described in Fig. 3. Protein markers are indicated on the left.o three latent antigens, EBNA3C, EBNA2, and EBNALP. pestern blot analysis for detection of these specific
roteins indicated that although LANA was expressed in
he coinfected cells as shown in Fig. 5A, lanes 1 and 2,
o EBNA2 or EBNA3C was detected in BC-1 and BC-2
Figs. 5B and 5C, respectively). In control lanes B95–8
nd LCL-1, a recently derived LCL expressing the entire
anel of latent antigens, specific signals were seen for
BNA2 and EBNA3C in both controls. These signals
ere not observed in cell lines BC-1 and BC-2 even in
anes 1 and 2 where fivefold (1 million cells) were added
o as to allow for detection of low-level expression in
hese cell lines. Specific protein expression for EBNALP
sing the specific monoclonal antibody JF186 (Finke et
l., 1987) identified no specific bands, demonstrating that
BNALP was not expressed in these cell lines (data not
hown). These results lead us to believe that expression
f the major essential EBNAs were restricted in these
oinfected cell lines. This may be due to the expression
f one or more alternative regulatory factors from the
SHV genome including LANA as well as cellular factors
hat are induced on infection with KSHV. Restriction of
FIG. 5. Western blot analysis of BC-1 and BC-2 for detection of LANA,
KSHV latent antigen, EBNA2, and EBNA3C, two essential EBV latent
enes important for EBV immortalization of B-lymphocytes. (A) Western
lot for analysis of LANA expression using human serum that recog-
izes LANA. (B) Western blot detecting EBNA2 expression using a
pecific monoclonal antibody PE2. (C) Western blot detecting EBNA3C
sing a specific monoclonal antibody A10 (Maunders et al., 1994).
BNA2 and EBNA3C are not detected in BC-1 and BC-2. However
ANA is expressed in both cell lines. The positive control cell lines
95–8 and LCL1 both express EBNA2 and EBNA3C [seen in (B) and (C)
n lanes 3 and 4]. BJAB is an EBV- and KSHV-negative cell line in lane
. BC-1 and BC-2, lanes are from cell lysates of 1 million cells and
ontrol lanes represent cell lysate from 200,000 cells. Positions of
rotein markers are indicated on the left.
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23VIRAL ANTIGEN EXPRESSION IN COINFECTED BODY-CAVITY-BASED LYMPHOMAS CELLSxpression of the essential EBNA proteins from the ma-
or Cp and Wp promoters is similar to that seen with type
I latency in previously described malignancies (naso-
haryngeal carcinoma or Hodgkin’s lymphoma).
etection of early antigen expression in BC-1
nd BC-2
For detection of the spontaneous expression of EBV
arly antigens, we used a human serum capable of
etecting early antigens previously characterized and
esignated as HS-4 in this study (Robertson et al., 1994).
his serum recognizes the EA-D complex ranging from
3 to 56 kDa along with the BALF2 ORF encoding the
ingle-stranded DNA binding protein and other open
eading frames (ORFs) usually seen in EBV-infected cells
ndergoing active replication (Robertson et al., 1996). We
how that BC-1 had a low level of EA-D antigens as seen
n Fig. 6A, whereas, BC-2 had undetectable levels of
arly antigens. The panel of proteins indicated by the
rrow on the right shows a range of proteins in the B95–8
ells that usually contain polymerase accessory proteins
mportant for replication (Kieff, 1996; Robertson et al.,
994). A larger band at ;135 kDa indicates the expres-
FIG. 6. Western blot analysis of EBV lytic protein expression in BC-1 a
and 4 represents protein fractionated from cell lysates prepared fro
quivalent amounts of BJAB, a negative control cell line. (A) Lighter exp
ingle-stranded DNA binding protein expressed from BALF2 p135 wa
ccessory proteins for DNA replication and migrating between 45 to 56
o lytic antigen signal was detected from BC-2 using this human serum
re indicated on the left. Positions of lytic antigens are indicated on thion of the single-stranded DNA binding protein encoded py the BALF2 open reading frame (Fig. 6A). A darker
xposure of a similar membrane with cell lysate from 1
illion cells incubated with the same human serum
emonstrated that BC-1 expressed a number of the early
roteins and the single-stranded DNA binding protein.
owever, BC-2 had no specific signal for any lytic early
ntigens using this human serum (Fig. 6B).
Analysis of the immediate early transactivator BZLF1
nd the early antigen BMRF1 expression levels demon-
trated that the transactivator BZLF1 was expressed in
C-1. This signal was seen at a slightly slower mobility
ue to the repeated elements within the coding se-
uence (Farrell, 1993) than that seen in the control B95–8
xpressing BZLF1 and has low levels of lytic replication
lane in Fig. 7B). R3 monoclonal antibody (Pearson et al.,
983) detected BMRF1 another early antigen protein. It
hows different sizes that also may be due to repeated
lements in BamM region of EBV (Farrell, 1993). This
ndicates that these cell lines, BC-1 and BC-2, are un-
ergoing low levels of early antigen expression before
he production of progeny virion particles occurring from
small number of cells in the population. BC-1 demon-
trates a greater potential for spontaneous viral progeny
. Lanes 1 and 2 contain cell lysate prepared from 1 million cells. Lanes
000 LCL1 and B95–8 (EBV-positive cell lines) cells. Lane 5 was from
of a similar blot; (B) Longer exposure of the same cell lines in (A). The
in BC-1 and B95–8. The early antigen complex (EA-D) that includes
s seen in BC-1 and B95–8 (Robertson and Kieff, 1995Robertson, 1997).
) capable of detecting a number of EBV lytic proteins. Protein markers
of (A) and (B).nd BC-2
m 200,
osure
s seen
kDa wa
(HS-4roduction.
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24 CALLAHAN ET AL.ross-reactivity of human antisera to EBV and KSHV
ntigens
Ascites from patients with pleural effusion lymphomas
ere obtained and adsorbed against two rounds of an-
igens from a sonicated mixture of EBV-negative and
positive B cells (BJAB and B95–8, respectively) followed
y centrifugation for clarification. Patients were HIV pos-
tive with diagnosed Kaposi’s sarcoma. The supernatant
as diluted 1:100 for Western blotting in phosphate-
uffered saline and designated as HS-5. The cell lysates
rom each cell line infected with KSHV were prepared at
million cells, and the EBV-positive control cell line
95–8 was used for detection of the possible reactive
iral antigens. Figure 8A indicates that a specific gene
roduct (gp) migrating ;110 kDa recognized by a human
ntiserum was specific for a viral gene product, and this
roduct was not seen in the negative control BJAB lane.
nother specific viral gp ;41–42 kDa in size was spe-
ifically detected in the viral lanes but not in the EBV- or
SHV-negative lane BJAB (Fig. 8B). Therefore antibodies
rom human serum with specificity for KSHV antigens
an potentially cross-react with similar EBV antigens.
Additional blots incubated with human serum from
SHV- and HIV-negative patients adsorbed against EBV-
FIG. 7. Western blot analysis for immediate early lytic antigens BZLF1
nd an early antigen BMRF1. (A) Western blot analysis using a specific
onoclonal antibody R3 against BMRF1 (Pearson et al., 1983). (B)
nalysis for using a specific monoclonal against BZLF1 (Young et al.,
991). The immediate early transactivator BZLF1 was detected in BC-1
ut not in BC-2 (compare lanes 1 and 2). BMRF1 was detected in both
C-1 and BC-2 (lanes 1 and 2), and a nonspecific band is detected in
ll the lanes migrating above the BMRF-1 proteins. Lanes 1 and 2
orresponds to cell lysate from 1 million cells. Markers are indicated on
he left and signals for BZLF1 and BMRF1 are indicated on the right.
ote that signal for BZLF1 and BMRF1 are migrating larger in BC-1 and
C-2 compared with that in the wild-type B95–8 cell line.egative BJAB cell antigens indicated that there was also fome cross-reactivity to early antigens (see Fig. 9A, lane
in BCBL1 cell line). Only EBNA1 expression was ob-
erved in the coinfected cell lines (Figs. 9A and 9B, lanes
and 2). These data suggests that cross-reactivity exist
etween EBV and KSHV human antibodies against some
imilar early and lytic proteins from both viral agents. The
ene product, gp41–42 is similar to that seen in the
nalysis of KSHV proteins by other groups where KSHV
atient serum can react with viral lytic glycoproteins and
ay be encoded by the K8.1 ORF (Raab et al., 1998).
imilarly, the gene product, gp110, detected by the KSHV-
ositive human serum may be similar to that of gp110 in
BV and potentially be the KSHV homolog encoded by
RF8 gB protein (Russo et al., 1996).
DISCUSSION
The program of EBV or KSHV gene expression in a
ually infected body-cavity-based lymphoma cell line
ay be distinct from that observed in a singly infected
BV or KSHV cell line. The established coinfected cell
ines provide a means to evaluate the ability of specific
enes of one viral agent to regulate the expression of a
epertoire of latent and lytic genes encoded by the other
iral agent. Our studies attempted to analyze expression
f specific latent and lytic genes encoded by these two
iral agents using specific antibodies to the viral-en-
oded proteins in two coinfected EBV and KSHV cell
ines established from body-cavity-based lymphoma pa-
ients. Both EBV and KSHV belong to the gammaherpes-
irus family and have collinear homology to other gam-
aherpesviruses (Russo et al., 1996; Neipel et al., 1997).
BV encodes a number of genes essential for human B
ell immortalization (Robertson and Kieff, 1995a,b; Rob-
rtson, 1997; Rickinson and Kieff, 1996). These genes are
nvolved in the dysregulation of a number of cellular
ignaling pathways crucial for EBV-induced B cell prolif-
ration, including the Notch signaling pathway and the
umor necrosis factor signaling pathway (Aster et al.,
997; Mosialos et al., 1995). Previous work by two groups
redominantly using rtPCR analysis was conflicting; this
ay have been due to lack of specificity using the rtPCR
tudies (Horenstein et al., 1997; Szekely et al., 1998). We
herefore investigated the protein expression of these
BV essential latent genes using specifically tested an-
ibodies to determine the type of latency expressed by
BV in the coinfected cell lines. This also will demon-
trate effects of coinfection on regulation of EBV gene
xpression that may contribute to the development of
ody-cavity-based lymphomas in immunocompromised
atients.
On the basis of our results of latent protein expression
rom the two coinfected cell lines, BC-1 and BC-2, we
ave demonstrated using specific human antiserum ca-
able of detecting the entire panel of latent EBNA genesrom EBV that EBNA1 is preferentially expressed albeit at
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25VIRAL ANTIGEN EXPRESSION IN COINFECTED BODY-CAVITY-BASED LYMPHOMAS CELLSower levels in these coinfected lines. No specific signal
as seen for EBNA2 although in the initial blot EBNA1
omigrated with the supposed position of the EBNA2
rotein. On further investigation using an EBNA1-specific
olyclonal serum, we have determined that this larger
ignal was indeed EBNA1. Additionally, even after load-
ng fivefold more cells from BC-1 and BC-2, no signal was
een for EBNA2, EBNALP, and the EBNA3 family of pro-
eins. Therefore the results from our Western blot data
ndicate that EBNA1 was the predominant EBNA protein
etected and support previous preliminary investigations
sing rtPCR results and expression levels in one of the
ell line BC-1 (Horenstein et al., 1997; Szekely et al.,
998). We then analyzed the LMP1 protein expression
sing a monoclonal antibody specific for LMP1 (Mann et
l., 1985). Our data demonstrated that LMP1 was ex-
ressed in both BC-1 and BC-2 at levels lower than the
ontrol EBV-infected cell lines with ,30% of the cells
aving positive signal by immunofluorescence analysis.
he signal was easily detected by Western blot in cell
ysates from 1 million cells. There was some level of
1LMP1 expression markedly lower than that seen in
95–8 cells. Additionally, immunofluorescence data us-
ng the LMP1 monoclonal and a human serum that de-
ects EBNA1 specifically (tested by Western blotting)
upported the Western blot data that EBNA1 and LMP1
re expressed in both BC-1 and BC-2 cell lines. The
xpression is, however, at a reduced level compared
ith the EBV-positive cell line IB4 where most of the cells
ere positive for both LMP1 and EBNA1. The LMP1
xpression was not seen with formation of the typical
arge foci or clumps at the cell membrane but had sig-
FIG. 8. Western blot analysis of KSHV gene expression using hum
dsorbed against B cell and EBV antigens to remove antibodies again
SHV-specific antibodies recognizing KSHV antigens ;110 kDa and a
omparison of lanes 3 and 4 (singly infected KSHV cell lines) with lane
C-2 are coinfected with both EBV and KSHV (Cesarman et al., 1995b
nd p41–42, indicating that these are specific viral antigens. Markers f
ndicated on the right.als that were smaller, less intense, and diffused, al-hough the signals were localized at the same specific
egions at the membrane. EBNA1 had a punctate signa-
ure but was less intense compared with the IB4 and was
imilar to the levels expected when compared to the
estern blot data. These data are contrary to that shown
reviously for BC-1 where LMP1 was not detected pos-
ibly due to the reduced levels in these coinfected cells
hown in our experiments and the sensitivity of the
revious experiments looking at BC-1 (Szekely et al.,
998).
In an effort to address the expression of KSHV latent
uclear antigens, we investigated the levels of LANA by
mmunofluorescence and Western blot analyses. LANA
as expressed at higher levels in BC-1 and BC-2 com-
ared with EBNA1 and was detected in .95% of the cells
rom both BC-1 and BC-2. Specific analysis targeting the
dditional EBNA proteins that are major essential EBV
ntigens EBNA2 and EBNA3C did not show any evi-
ence of expression using specific monoclonal antibod-
es by Western blot and immunofluorescence analysis.
nalysis of EBNALP also did not show any specific
ignal (data not shown). Analysis of LMP2 expression by
mmunofluorescence indicated low-level expression in
C-1 and BC-2 (data not shown). Therefore our protein
ata using specific antiserum against the EBV and KSHV
atent antigens are similar to that shown by rtPCR tran-
cription data (Horenstein et al., 1997) in one set of
nalysis but differs from that shown in other analysis
Szekely et al., 1998). Our analysis of direct protein ex-
ression represents a comprehensive study looking at
xpression of specific essential latent EBV antigens and
ytic proteins in these coinfected cells.
m from a patient with Kaposi’s sarcoma. Human serum (HS-6) was
onspecific B cell and EBV antigens. This analysis demonstrated that
t ;41–42 kDa can cross-react with EBV antigens seen in (A) and (B).
ly infected EBV cell lines) shows similar bands in all lanes. BC-1 and
egative control cell line BJAB has no specific signal for antigen p110
determination are indicated on the left and specific viral antigens arean seru
st the n
double
5 (sing
). The n
or sizeEBV latency I and II do share similarity in the transcrip-
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26 CALLAHAN ET AL.ion of EBNA1 from the Q/U/K locus, and transcription
as clearly demonstrated by two independent studies
Horenstein et al., 1997; Szekely et al., 1998) and sup-
orted by our Western blots and immunofluorescence
ata. Our experiments, however, show that LMP1 was
etected in .20% of the BC-1 and BC-2 cells but more
pecific by Western blots albeit at lower levels compared
ith the typical EBV latency type III infected cells. EBER
nd LMP2A transcripts were previously detected by rt-
CR, and LMP2B was not detected (Horenstein et al.,
997). LANA expression was consistently higher than
BNA1 in our studies, indicating that LANA may be
mportant in the continued persistence of KSHV in the
C-1 and BC-2 cells and may potentially have a role in
egulating transcription from the major Wp or Cp promot-
rs. We are currently pursuing experiments attempting to
ddress this possibility.
The expression of EBNA1 in these primary effusion
ymphomas using the Q/U/K splicing arrangement is
imilar to that seen in Burkitt’s lymphomas having a type
pattern of latency (Rickinson, 1996; Sample et al., 1991)
nd suggests that EBNA1 may provide crucial functions
FIG. 9. Western analysis for detection of cross-reactivity for EBV lytic
ntigen in singly infected KSHV cell lines BC-3 and BCBL1 (lanes 3 and
). Cell lysates from 1 million cells were fractionated in lanes 1–4 and
rom 500,000 cells in lanes 5–7 by 8% SDS–PAGE. (A) Western blot
sing human serum from an EBV-positive, KSHV-negative individual
apable of detecting EBV lytic antigens. (B) Same membrane stripped
nd reprobed with human serum (HS-7) detecting the EBV latent EBNA
roteins. Markers are noted on the left and signals for specific antigens
re indicated on the right. Note that both EBNA1 and EBNA2 signal is
isible in LCL1 and B95–8 lanes using this human serum.or driving these lymphomas in humans. In one study, B tell lymphomas were induced in transgenic mice ex-
ressing EBNA1 (Wilson et al., 1996). EBNA1 has a cru-
ial role in the maintenance of EBV episomes in infected
ells, and experiments to date linking EBNA1 to replica-
ion functions have not been successful (Aiyar et al.,
998). Therefore the role of EBNA1 in maintenance of
BV episomes and other functions that includes its role
n transcription regulation may provide the necessary
equirements for driving the body cavity based lympho-
as (Gahn and Sugden, 1993, 1995). In addition, the
xpression of LANA from the KSHV genome may provide
synergistic role in the development of these lympho-
as in immunocompromised patients possibly through
ts activities in transcription regulation or modulation of
ignal transduction pathways in the infected cells. Po-
ential similarities in functions between EBNA1 and
ANA in terms of the maintenance of the KSHV episome
nd also potential transcription regulation of viral and
ellular promoters may provide important clues for un-
erstanding the requirement for coinfection. Additionally,
ANA may substitute for the EBV EBNA2 and EBNA3s,
he expression of which may allow for targeting of the
ost by the immune surveillance if LANA is less suscep-
ible to detection. Further experiments addressing these
ypotheses will elucidate mechanisms of action of LANA
nd EBNA1 in induction of the body-cavity-based lym-
homas.
On the basis of two conflicting previous reports on
MP1 expression in BC-1 and BC-2, we decided to take
closer look at the LMP1 protein levels in these two cell
ines using the specific LMP1 monoclonal antibody
Mann et al., 1985). LMP1 was clearly detected in both
C-1 and BC-2 by immunofluorescence studies and
estern blot analysis. This is distinct from previous re-
ults in BC-1 indicating that little or no LMP1 was de-
ected (Szekely et al., 1998). Immunofluorescence analy-
is of LMP2A expression using specific LMP2A mono-
lonal antibody (Fruehling et al., 1998) indicated that
here was expression in BC-1 and BC-2 (E.S.R., unpub-
ished observation). We therefore have demonstrated
hat in the BC-1 and BC-2 coinfected cell lines EBNA1,
MP1, and LMP2A are expressed similarly to that of a
atency type II infection seen in nasopharyngeal carci-
oma and Hodgkin’s lymphoma (Henle et al., 1969; Henle
nd Henle, 1976; Pallesen et al., 1991). Moreover, the
evels of LMP1 were lower than typical type III latency. In
his respect, LMP1 expression may be required in much
maller amounts in the coinfected cell lines although not
ompletely dispensable for driving the proliferative
vents in body cavity based lymphomas. Additionally, the
resence of the KSHV virus and expression of genes
rom its genome can provide the necessary require-
ents for continued proliferation of these cells. This
attern of latent gene expression observed in BC-1 and
C-2 may be crucial for the sustained development ofhese types of lymphomas in vivo. The fact that body-
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27VIRAL ANTIGEN EXPRESSION IN COINFECTED BODY-CAVITY-BASED LYMPHOMAS CELLSavity-based lymphoma cell lines singly infected with
SHV have been isolated and because one would expect
hat .75–80% of the population to be infected with EBV
Boyle et al., 1991, 1993a,b; Shibata et al., 1993), it is
ossible that in cases where only KSHV is found in
ymphoma cells EBV may have previously been a con-
ributor to the proliferative process and that KSHV can
urther maintain this event in the absence of EBV infec-
ion. Also, the fact that the levels of EBV latent gene
xpression in these cells is lower than expected when
ompared with wild-type EBV infection (for both EBNA1
nd LMP1), we can speculate that in vivo, where detec-
ion of EBV latent genes may be detrimental for a sus-
ained infection, EBV might be more of a liability than an
sset. Therefore the functions of the other latent proteins
ay be limited to early periods in development of these
ymphomas where KSHV is a coinfecting agent. KSHV
herefore may play an important role in the maintenance
nd development of body-cavity-based lymphomas. The
act that KSHV can induce proliferation of human endo-
helial cells with the genome present in only a subset of
he population is suggestive of and may point to only a
imited capability of KSHV to truly induce immortalization
f endothelial cells and other human cells (Flore et al.,
998). The passenger hypothesis may still be a viable
ne and more experiments will shed light on the true
bilities of KSHV as a transforming virus.
Our studies of the lytic gene expression in these cell
ines provide clues as to the nature of the productive
nfection. We have detected expression of both the sin-
le-stranded DNA binding protein p135 band expressed
rom the BALF2 ORF in BC-1 but not in BC-2. Early
ntigen expression indicated by BMLF1 early antigen
iffused (Farrell, 1993) was also seen in BC-1 and was
ot detected in BC-2 even after prolonged exposure.
imilarly, BZLF1, the immediate early lytic transactivator,
as detected in BC-1 but not in BC-2 cells. However,
nother early antigen expression BMRF1 was seen in
oth BC-1 and BC-2, although the size of the protein as
etected by the specific monoclonal antibody varied from
5 to 43 kDa. This could be due to alternate splicing or
epeated elements in the BMRF1 ORF resulting in pro-
uction of transcripts of varying size (Farrell, 1993) or
ome aberrant recombination event in the EBV genome
f these cell lines. It is possible that BC-1 has a larger
ool of spontaneously lytic cells in the cell population
han BC-2 although not necessarily more competent in
roduction of progeny virus when induced by chemical
gents like sodium butyrate and phorbol esters (Miller et
l., 1997).
Serum from a KSHV-positive patient with body-cavity
ymphoma adsorbed against EBV and B cell antigens
BJAB and B95–8 cells) were able to detect KSHV anti-
ens that cross-reacted with similar antigens in EBV
ingly infected cells. A single band ;110 kDa in size anddoublet ranging from 41 to 42 kDa in size were ob- aerved in the EBV and KSHV coinfected cell lines, the
SHV singly infected cell lines, and the EBV cell line
95–8 but not in the negative control B cell. Neither
ANA nor any other EBV-specific latent or lytic antigen
ased on subsequent blots was detected with this serum
ample. This strongly suggests that some EBV antigens
specifically a gene product gp110 and gp41–42) can be
ecognized by serum that recognizes KSHV antigens.
mportantly, a single band in the KSHV-infected cell line
CBL1 corresponding to one of the EA-D proteins was
etected, suggesting that antibodies against the early
ntigen complex from EBV can recognize a similar anti-
en encoded by KSHV. Hence, our data indicate that in
ody-cavity-based lymphomas infected with KSHV and
BV, viral gene expression is determined by a number of
actors including coinfection with other infectious agents,
he specific cell compartment of the body infected with
he virus, and other cofactors that may influence the
bility of the infected cells to continually survive in vivo.
The previous discrepancies in assignment of a clear
dentity of latency to the EBV genome infecting the BC-1
nd BC-2 cell lines is probably due to the small differ-
nces in latency I and II. The specific latent genes
xpressed are almost identical except for the expression
f LMP seen in type II latency. Our data strongly support
his determination that BC-1 and BC-2 both express
MP1 and LMP2A and therefore have all the criteria for
ype II latency similar to that seen in nasopharyngeal
arcinoma and Hodgkin’s lymphomas. EBNA1 is the only
BNA protein expressed as determined by extensive
nalysis using Western blot and immunofluorescence
nalyses. Some level of spontaneous lytic replication is
een in these cells based on the expression of the
mmediate early BZLF1 gene and early antigens seen in
he Western blots for specific lytic antigens. This is not
urprising because all forms of latency can spontane-
usly undergo lytic replication in culture and also may
witch to latency III on continual passage in culture
Rickinson, 1996). It is left to be determined if BC-1 and
C-2 can undergo such a switch after prolonged pas-
age in culture. The meaning of the existing similarities
f these two PEL cell lines to that seen in nasopharyn-
eal carcinoma and Hodgkin’s lymphomas is an inter-
sting question. Further studies may demonstrate that
hese types of cancer have modes of proliferation that
equire similar signaling events triggered by viral latent
ene products crucial to the continual proliferation of the
ells resulting in the development of these cancers.
MATERIALS AND METHODS
ntibodies and cell lines
Antibodies used for analysis of the latent EBNAs were
btained from a patient sample previously characterized
or identification of each of the EBNA proteins (Robertson
nd Kieff, 1995a). Samples were adsorbed against an
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28 CALLAHAN ET AL.BV-negative Burkitt’s Lymphoma cell line BJAB cell ly-
ate or BJAB and B95–8 cell lysate at 4°C for 48 h. The
uman polyclonal sera samples are designated as HS-1
o HS-7 for clarity in the manuscript. HS-1 recognizes all
he EBNA proteins; HS-2 recognizes EBNA1; HS-3 rec-
gnizes LANA; HS-4 recognizes the ssDNA binding pro-
ein (p135), the EA complex, EBNA1, EBNA2 and BZLF1;
S-5 recognizes antigens referred to as gene product
41–42 and p110; HS-6 recognizes the EA complex,
BNA1, EBNA2, and p135; and HS-7 recognizes the
BNA3s, EBNA1, and EBNA2. Serum was diluted at 1:50
ilution in PBS with 1 mM sodium azide for use. Hybrid-
mas cell lines producing monoclonal antibodies PE2,
10, JF186, and S12 were cultured and the supernatant
sed as a 1:2 dilution in PBS with 1 mM sodium azide.
ntiserum recognizing the EBV lytic antigens were ob-
ained from patient samples previously characterized
Robertson et al., 1994). The serum was typically diluted
n PBS 1:50 dilution after absorption with cell lysate from
he EBV-negative cell line BJAB.
BJAB is an EBV-negative cell line obtained from Elliott
ieff. BC-1, BC-2, and BC-3 were purchased from the
TCC. BCBL-1 was obtained from the National Institutes
f Health AIDS Research and Reference Reagent Pro-
ram (Kedes et al., 1997). BC-1 and BC-2 are coinfected
ith both KSHV and EBV (Cesarman et al., 1995b). BC-3
nd BCBL-1 are singly infected with KSHV (Arvanitakis et
l., 1996; Kedes and Ganem, 1997; Picchio et al., 1997).
95–8 cell line is infected with type I EBV (Miller et al.,
972, 1974). LCL-1 is a recently derived lymphoblastoid
ell line (LCL) created in our lab by infection of primary
uman B-lymphocytes with B95–8 virus.
estern blotting analysis
To account for the possibility that low levels of viral
roteins may be expressed in BC-1 and BC-2, equivalent
mounts of cell lysates were used from B95–8, LCL-1,
nd BJAB and the number of BC-1 and BC-2 cells used
or preparation of cell lysates was increased to fivefold
hat of the controls. Cell lysates from 200,000 control
ells were prepared along with lysates from 1,000,000
ells for BC-1 and BC-2. Cell lysates were analyzed by
ractionating by 7 or 8% sodium dodecyl sulfate poly-
crylamide gel electrophoresis (SDS–PAGE). The pro-
eins were transferred to 0.45 mm Bio-Rad nitrocellulose
embranes. Membranes were analyzed with specific
ntibodies based on the protocol supplied by the man-
facturer. For analysis of the latent antigens using hu-
an serum, membranes were incubated at 4°C over-
ight and washed in PBS and secondary antibody Pro-
einA-HRP at a 1:7500 dilution (Amersham). Hybridoma
upernatant from cell lines producing antibodies against
BNALP, EBNA2, EBNA3C, and LMP1 were incubated for
4 h at 4°C and washed in PBS and secondary anti-
ouse-HRP at a 1:2500 dilution (Amersham). The pro-eins were detected by chemilluminescence using re-
gents from Amersham.
mmunofluorescence analysis for detection of specific
ntigens
EBV-negative (BJAB) and -positive (IB4) cell lines were
sed as controls for analysis of EBV-specific latent anti-
ens. BC-1 and BC-2 were used as coinfected cell lines
or EBV and KSHV. The cells were fixed by methanol:
cetone 1:1 (for anti-EBNA1 and anti-LANA) or methanol
for anti-LMP1) for 15 min at 220°C. The hybridoma for
nti-LMP1 S12 (Mann et al., 1985) was used as neat
ybridoma supernatant, anti-EBNA1 at 1:50 dilution of a
uman serum reactive against EBNA1 and another hu-
an serum reactive against LANA at 1:1000. Secondary
ntibodies for detection of S12 was FITC goat anti-mouse
rom Jackson (No. 715–095-151) and for the human serum
oat anti-human from Molecular Probes all used at
:1000 dilution. Visualization of the signals was done
sing a PCM 2000 Nikon confocal microscope. All cap-
ured photographs then were transferred as tiff files into
orel Draw 8.0 and presented as a montage.
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